The U.S. FDA has granted fast track designation to treatment with CLD-201, an oncolytic virus, for patients with soft tissue ...

FDA grants fast track designation to CLD-201, an innovative therapy for soft tissue sarcoma, enhancing its development and ...

Soft Tissue Sarcoma or Malignant Mesenchymal Tumors in the First Year of Life: Experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee Authors: D.

A groundbreaking study led by Children's Hospital Los Angeles has found a novel mechanism behind neuroblastoma progression: the shape and structure of the extracellular matrix.

The Global Chondrosarcoma Market is witnessing significant advancements, particularly in diagnostics and treatment options for this rare cartilage-forming cancer. Innovations in radiographic imaging, ...

A study by Tianjin First Central Hospital researchers reveals the miR-451/ETV4/MMP13 signaling axis as a critical regulator of NSCLC progression. Findings show miR-451 suppression activates ETV4-MMP13 ...

Patients with stage III disease treated with a novel six-drug combination showed improved survival compared with the Malignant Mesenchymal Tumor 84 study (MMT 84; 5-year OS, 60% v 42%, respectively).

ADCE-D01 is a first-in-class ADC targeting uPARAP conjugated to the Topo-1 inhibitor payload P-1021. uPARAP is a novel endocytic ADC target that is overexpressed in tumors of mesenchymal origin ...

Among patients with gastrointestinal stromal tumors (GIST), the most common mesenchymal tumor of the GI tract, treatment with bezuclastinib (CGT9486) and Sutent (sunitinib) demonstrated acceptable ...